Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome (VALENA)
Phase II Study for the Determination of Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome With Favorable Risk Profile
Sponsor: Heinrich-Heine University, Duesseldorf
Terminated
delayed recruitment
Other terminated trials from Heinrich-Heine University, Duesseldorf
- Hand-foot Syndrome · Phase PHASE2 · Dec 2018
- Colorectal Cancer Metastatic · Phase PHASE2 · Oct 2017
- Relapsing Remitting Multiple Sclerosis · Phase PHASE4 · Feb 2016
- Bladder Cancer · Phase PHASE2 · Sep 2013
- Heparin Induced Thrombocytopenia (HIT) · Phase PHASE4 · Mar 2012
See all terminations from Heinrich-Heine University, Duesseldorf
Listed as NCT00977132, this PHASE2 trial focuses on Myelodysplastic Syndrome MDS and remains terminated or withdrawn. Sponsored by Heinrich-Heine University, Duesseldorf, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Oct 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Heinrich-Heine University, Duesseldorf
For direct contact, visit the study record on ClinicalTrials.gov .